Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (211-220 of 426) with videos related to

Pageof 43
Sort By:
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerDebashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Plos One|July 5, 2013
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate CancerSjoerd T Ligthart, Frank A W Coumans, Francois-Clement Bidard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancerJohann S de Bono, Josep M Piulats, Hardev S Pandha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical TrialsAngelika Terbuch, Crescens Tiu, Irene Moreno Candilejo, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
Pageof 43

Showing results (211-220 of 426) with videos related to

Sort By:
Pageof 43
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerDebashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Plos One|July 5, 2013
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate CancerSjoerd T Ligthart, Frank A W Coumans, Francois-Clement Bidard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancerJohann S de Bono, Josep M Piulats, Hardev S Pandha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical TrialsAngelika Terbuch, Crescens Tiu, Irene Moreno Candilejo, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
Pageof 43